NDATRANSDERMALSYSTEM
Approved
Dec 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
4/8 — Partial
TRANSDERM SCOP (scopolamine) by Baxter is cholinergic antagonists [moa]. Approved for nausea and vomiting, motion sickness. First approved in 1979.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRANSDERM SCOP is a transdermal patch containing scopolamine, an anticholinergic agent that blocks cholinergic neurotransmission to prevent nausea and vomiting. It is indicated for motion sickness and post-operative nausea, and works by antagonizing muscarinic cholinergic receptors in the chemoreceptor trigger zone and vestibular system.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30%), brand teams are focused on lifecycle extension and niche market retention rather than expansion.
Mechanism of Action
Cholinergic Antagonists
Pharmacologic Class:
Anticholinergic
Indications (2)
Clinical Trials (10)
PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor
Started Mar 2025
0Muscarinic Receptor Occupancy
TAK-071 Scopolamine-Induced Cognitive Impairment Study
Started Nov 2016
18 enrolled
Healthy Volunteers
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
Started May 2016
128 enrolled
Motion Sickness
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
Started Jan 2014
27 enrolled
Memory ImpairmentAlzheimer's Disease
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
Started May 2011
88 enrolled
Healthy
Worked on TRANSDERM SCOP at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.